Wolfgang Landgraf

medical department

H指数:21

被引数:1,681

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes

Ahlqvist 亚表型在2型糖尿病中的研究：科学证据的叙事性综述及其对精准糖尿病的潜在贡献

DIABETES OBESITY & METABOLISM

IF5.7

2026-10-070

OAAI

Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes

针对甘精胰岛素治疗的2型糖尿病亚型患者餐后高血糖以实现HbA1c目标的的重要性

Diabetes, Obesity and Metabolism

IF0

2025-11-030

OAAI

Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial

新定义的2型糖尿病亚型对基础甘精胰岛素300 U/ml和甘精胰岛素100 U/ml的治疗反应: 第3版随机临床试验的事后分析

DIABETES OBESITY & METABOLISM

IF5.7

2023-10-201

Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naive people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics

DIABETES OBESITY & METABOLISM

IF5.7

2023-06-133

Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2022-08-015

OAAI

Indirect treatment comparison of efficacy and safety of insulin glargine 300 U/mL with once-daily-insulin premix in T2DM

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2022-04-010

OAAI

Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naive people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial

DIABETES OBESITY & METABOLISM

IF5.7

2020-05-295

OAAI

Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL

空腹c肽，初始基础甘精胰岛素100 U/mL的2型糖尿病患者的低血糖风险的生物标志物

DIABETES OBESITY & METABOLISM

IF5.7

2019-11-0715

PREAI

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

2型糖尿病患者开始甘精胰岛素100 U/mL治疗: 实现HbA1c目标小于7.0% 的决定因素

DIABETES OBESITY & METABOLISM

IF5.7

2019-01-1018

OAAI

Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus

在先前未使用胰岛素的2型糖尿病患者中，用甘精胰岛素100 U/mL滴定的前8周的低血糖风险

DIABETES OBESITY & METABOLISM

IF5.7

2018-07-226

High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c <7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL

DIABETES

IF7.5

2018-07-010

PRE

Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2018-01-0122

PREAI

Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2017-07-278

OAAI

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

CARDIOVASCULAR DIABETOLOGY

IF10.6

2017-05-199

OAAI

Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy

根据伴随的口服抗糖尿病治疗，开始使用甘精胰岛素100 U/mL或中性鱼精蛋白的2型糖尿病患者的疗效和低血糖的患者水平荟萃分析

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2017-02-0134

OAAI

Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents - a randomized, prospective, crossover, open clinical trial

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2015-06-0914

OAAI

NEW META-ANALYSIS OF PATIENT-LEVEL DATA ON EFFICACY AND HYPOGLYCAEMIA WITH INSULIN GLARGINE OR NPH INSULIN IN TYPE 2 DIABETES MELLITUS (T2DM) ACCORDING TO CONCOMITANT ORAL THERAPY

VALUE IN HEALTH

IF6

2014-11-012

OAAI

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2014-11-0138

OAAI

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes

使用低血糖敏感算法调节胰岛素剂量滴定: 甘精胰岛素与中性鱼精蛋白在未接受胰岛素治疗的2型糖尿病患者中的比较

DIABETES OBESITY & METABOLISM

IF5.7

2014-07-1218

OAAI

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes

ACTA DIABETOLOGICA

IF2.9

2013-02-2134

OAAI

Wolfgang Landgraf

个人简介

教育背景

工作经历

荣誉奖项

研究方向